

**PerCP anti-mouse Ly-6G/Ly-6C (Gr-1)**

**Catalog # /** 1142130 / 100 µg  
**Size:** 1142125 / 25 µg

**Clone:** RB6-8C5

**Isotype:** Rat IgG2b, κ


**Immunogen:** Raised against granulocytes of mouse origin

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions. The solution is free of unconjugated PerCP and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** 0.2



C57BL/6 mouse bone marrow (gated on myeloid cell population) stained with Ly-6G/Ly-6C (clone RB6-8C5) PerCP (filled histogram) or rat IgG2b, κ PerCP isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

\* PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.

**Application Notes:** Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C<sup>19</sup>. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8<sup>19</sup>. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4<sup>20</sup>.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes *in vivo*. Additional reported applications (for relevant formats of this clone) include: *in vitro* complement-mediated cytotoxicity<sup>2</sup>, *in vivo* depletion<sup>3-5,9</sup>, immunoprecipitation<sup>1</sup>, immunohistochemical staining<sup>6</sup> (including paraffin-embedded sections<sup>9,16</sup>, acetone-fixed frozen sections<sup>11</sup> and zinc-fixed sections<sup>15</sup>), and Western blotting<sup>7</sup>. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)<sup>20</sup>.

**Special Note:** The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108414). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

**Application  
References:**

1. Fleming TJ, et al. 1993. *J. Immunol.* 151:2399. (IP)
  2. Brummer E, et al. 1984. *J. Leukocyte Biol.* 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. *J. Exp. Med.* 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. *J. Virol.* 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. *J. Immunol.* 152:1836. (Deplete)
  6. Nitta H, et al. 1997. *Cell Vision* 4:73. (IHC)
  7. Jutila MA, et al. 1988. *Eur. J. Immunol.* 18:1819. (WB)
  8. Engwerda CR, et al. 2004. *Am. J. Pathol.* 165:2123.
  9. Brown CR, et al. 2004. *Infect. Immun.* 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. *Nature Immunology* 6:1011. (FC) [PubMed](#)
  11. Li M, et al. 2006. *P. Natl. Acad. Sci USA* 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. *Blood* 109:1620. (FC) [PubMed](#)
  13. Fazilleau N, et al. 2007. *Nature Immunol.* 8:753. (FC) [PubMed](#)
  14. Heuser M, et al. 2007. *Blood* 110:1639. (FC) [PubMed](#)
  15. Wang T, et al. 2007. *Infect. Immun.* 75:1144. (IHC)
  16. Bosio CM, et al. 2007. *J. Immunol.* 178:4538. (IHC)
  17. Boehme SA, et al. 2009. *Int. Immunol.* 21:81. (IHC)
  18. Piao Y, et al. 2012. *Neuro Oncol.* 14:1379. [PubMed](#)
  19. Ribechini E, et al. 2009. *Eur. J. Immunol.* 39:3538.
  20. Ma C, et al. 2012. *J. Leukoc. Biol.* 92:1199.
- 

**Description:** Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

**Antigen  
References:**

1. Fleming TJ, et al. 1993. *J. Immunol.* 151:2399.
2. Jutila MA, et al. 1988. *Eur. J. Immunol.* 18:1819.
3. Goni O, et al. 2002. *Int. Immunol.* 14:1125.